Table 3. Comparison between baseline and end of study markers of hepatic and whole-body insulin sensitivity in non-diabetic participants grouped by change in erythrocyte DHA enrichment (⩾2% or <2%).
| Variables |
DHA ⩾2% (n=9) |
DHA <2% (n=7) |
||
|---|---|---|---|---|
| Baseline | End | Baseline | End | |
| Basal endogenous glucose production (Ra; μmol/min/kg FFM) | 15.2±0.8 | 14.4±0.7 | 13.4±0.7 | 14.0±1.0 |
| Low-dose insulin EGP (μmol/min/kg FFM) | 8.7±0.9 | 7.8±0.7 | 7.1±0.5 | 6.7±1.0 |
| High-dose insulin total body glucose disposal (Rd; μmol/min/kg FFM) | 35.0±3.1 | 34.3±4.2 | 30.4±3.5 | 35.9±5.5 |
| High-dose insulin total body glucose clearance (MCR; ml/min/kg FFM) | 7.17±0.84 | 6.79±0.75 | 6.12±0.73 | 7.26±1.16 |
| M-value (ml/min/kg) | 3.22±0.33 | 3.21±0.34 | 3.23±0.61 | 3.77±0.73 |
| Hepatic insulin sensitivity index (μmol/min/kg FFM; mU/l) × 102 | 0.54 (0.36, 0.82) | 0.63 (0.42, 0.89)a | 0.52 (0.30, 0.67) | 0.55 (0.46, 1.42) |
| Adipose-IR × 10-2 | 75.5±11.0 | 109.0±38.9 | 110.0±27.6 | 67.9±10.1 |
Abbreviations: DHA, docosahexaenoic acid; EGP, endogenous glucose production; FFM, fat-free mass; IR, insulin resistance; M-value, glucose infusion rate; MCR, metabolic clearance rate; Ra, Rate of appearance of glucose; Rd, rate of glucose disposal.
Data presented as mean±s.e.m. or median (25th, 75th percentiles).
a
P<0.01 between baseline and end of study measurements within the respective groups.